Medical Options for Advanced HFpEF/HFmrEF Patients: An Expert-Guided Virtual Ward Round

Published: 09 October 2024

  • Views:

    Views Icon 2864
  • Likes:

    Heart Icon 7
  • episode_image
    12m 47s
    Part 7 Audience Q&A
    Biykem Bozkurt, Muthiah Vaduganathan, Pardeep Jhund
Average (ratings)
No ratings
Your rating

Overview

Subtitles Available in: English, Français, Italiano, Español, Deutsch, 简体中文 and 日本語 (click the CC icon icon in the video bar to select the subtitles).

 

This video series is dedicated to tackling the complexities of managing HFpEF and HFmrEF patients, offering a comprehensive educational experience for healthcare professionals. Chairing the session, Dr Biykem Bozkurt (Baylor College of Medicine, US) is joined by renowned experts Prof Pardeep Jhund (University of Glasgow, UK) and Dr Muthiah Vaduganathan (Brigham and Women’s Hospital and Harvard Medical School, US).

 

During the roundtable, the faculty review two case studies from part one of the programme, offering their expert perspectives on managing high-risk HFmrEF/HFpEF patients, highlighting gaps and challenges. The series explores current guidelines, applying an evidence-based approach and an in-depth discussion including an audience Q&A. 

 

The live version of this roundtable was accredited. For the on-demand CME-accredited course, please click the link below:

 

 

 

Case Studies

Click the link below to see Part 1 of the programme:

 

 

This education was developed by Radcliffe Medical Communications (Eire) Ltd.

 

This programme is supported by an unrestricted educational grant from Bayer.

Learning Objectives

  • Describe the current limitations of HFmrEF/HFpEF GDMT in advanced patients
  • Select appropriate patients for advanced medical therapy
  • Recall recent trial data for novel therapeutic approaches
  • Use expert guidance to develop an evidence-based approach to managing advanced HFmrEF/HFpEF

Target Audience

  • Cardiologists
  • Internists
  • Heart Failure Specialists
  • General Practitioners
  • Nurse Practitioners
  • Cardiovascular Nurses
  • Allied Healthcare Professionals

More from this programme

Part 1

Introduction and Case Study Results

This first session sees the faculty review their own patient cases and review the audience results on managing high-risk HFmrEF/HFpEF patients.

Part 2

Exploring the Guidelines

Dr Biykem Bozkurt provides an overview of the current guidelines and unmet needs.

Part 3

Applying an Evidence-Based Approach: FINEARTS-HF

Dr Muthiah Vaduganathan presents the latest data on FINEARTS-HF.

Part 4

Applying an Evidence-Based Approach: MRAs in HF

Prof Pardeep Jhund presents the latest data on MRAs in HF.

Part 5

Practical Use of MRAs: Expert Discussion

The faculty discuss the challenges in managing high-risk HFmrEF/HFpEF patients and how the latest data can be applied.

Part 6

Patient Cases Revisited: How Were They Treated?

The faculty review the case studies and how these patients were treated.

Part 7

Audience Q&A

In the final chapter, the faculty engage with questions from the live audience and summarise their closing remarks on the roundtable. 

Faculty Biographies

Biykem  Bozkurt

Biykem Bozkurt

Dr Biykem Bozkurt is the Immediate Past President of the Heart Failure Society of America. 

Dr Bozkurt is a Professor of Medicine, an advanced heart failure and cardiac transplantation specialist, Medical Care Line Executive (Medicine Department Chair) at the DeBakey VA Medical Center; W.A. “Tex” and Deborah Moncrief, Jr., Chair; Mary and Gordon Cain Chair; Vice-Chair of Department of Medicine; Director of the Winters Center for Heart Failure and Associate Director of Cardiovascular Research Institute at Baylor College of Medicine. 

View full profile
Muthiah Vaduganathan

Muthiah Vaduganathan

Co-Director, Center for Cardiometabolic Implementation Science

Dr Muthiah Vaduganathan is a Cardiologist and Clinical Trialist at Brigham and Women’s Hospital and Harvard Medical School, Boston, US. He is co-director of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital. He serves as an Associate Editor of JACC and as US national ambassador to the ESC Heart Failure Association. His research focuses on drug development, clinical trials, and implementation of cardio-kidney-metabolic therapies, and he has authored or co-authored more than 700 peer-reviewed publications. He participates on study leadership of ongoing advanced-phase trials in cardio-kidney-metabolism and heart failure.

View full profile
Pardeep Jhund

Pardeep Jhund

Professor in Cardiology, University of Glasgow

Prof Pardeep Jhund is a Professor in Cardiology at the University of Glasgow, UK.

He trained in medicine at the University of Glasgow, and completed his general medical training in Edinburgh. During this time he also graduated with a MSc in Epidemiology from the London School of Hygiene and Tropical Medicine, London, UK.

Prior to this, he graduated from the University of Glasgow with a PhD in cardiovascular epidemiology, under the tutelage of Prof John McMurray, and completed his fellowship at The Brigham and Women’s Hospital, Boston, US.

Prof Jhund has a special interest in heart failure, around which he has published widely in leading international journals.

View full profile

Comments

You must be to comment. If you are not registered, you can register here.
Dragana Sarenac
3weeks
Although there was a bias present, It s a very comprenhensive and educational session.
We all should think of it and use more MRA in HFp/mrEF in our pts, because there is benefit.
And guidelines are just the path, and pts with AFIb. are those with real great benefit.